Evidence map›Paper›PMID 37849008›Full record

ReviewEuropean journal of medical research2023

Interaction of Clostridioides difficile infection with frailty and cognition in the elderly: a narrative review.

Maria-Jose Fernandez-Cotarelo, Jasmine Y Jackson-Akers, Stephanie E Nagy-Agren, Cirle A Warren

Open access · goldAbstract readReview
In one paragraph

Review in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Comparison ofJournal of clinical medicine · 2025
    Article
  10. Article
  11. The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Maria-Jose Fernandez-CotareloDepartment of Internal Medicine, Hospital Universitario de Mostoles, Faculty of Health Sciences, Universidad Rey Juan Carlos, Calle Doctor Luis Montes S/N, Mostoles, 28935, Madrid, Spain. mfcotarelo@salud.madrid.org.ORCID http://orcid.org/0000-0002-8072-6965
Jasmine Y Jackson-AkersDivisión of Infectious Disease and International Health, University of Virginia, Charlottesville, VA, USA.
Stephanie E Nagy-AgrenSection of Infectious Diseases, Salem Veterans Affairs Medical Center, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
Cirle A WarrenDivision of Infectious Disease and International Health, University of Virginia, Charlottesville, VA, USA.
University of Virginia · USCarilion Clinic · USUniversidad Rey Juan Carlos · ES

Funding

Alanyl-glutamine supplementation of standard treatment for C. difficile infectionR01AI145322 · NIAID · UNIVERSITY OF VIRGINIA · PI WARREN, CIRLE ALCANTARA · 2020 to 2024
$4.0M
NIAID NIH HHS R01 AI145322NIH HHS AI145322
6 · The paper itself

Abstract

purposeClostridioides difficile infection (CDI) is the leading cause of antibiotic-related diarrhea and healthcare-associated infections, affecting in particular elderly patients and their global health. This review updates the understanding of this infection, with focus on cognitive impairment and frailty as both risk factors and consequence of CDI, summarizing recent knowledge and potential mechanisms to this interplay.

methodsA literature search was conducted including terms that would incorporate cognitive and functional impairment, aging, quality of life, morbidity and mortality with CDI, microbiome and the gut-brain axis.

resultsAdvanced age remains a critical risk for severe disease, recurrence, and mortality in CDI. Observational and quality of life studies show evidence of functional loss in older people after acute CDI. In turn, frailty and cognitive impairment are independent predictors of death following CDI. CDI has long-term impact in the elderly, leading to increased risk of readmissions and mortality even months after the acute event. Immune senescence and the aging microbiota are key in susceptibility to CDI, with factors including inflammation and exposure to luminal microbial products playing a role in the gut-brain axis.

conclusionsFrailty and poor health status are risk factors for CDI in the elderly. CDI affects quality of life, cognition and functionality, contributing to a decline in patient health over time and leading to early and late mortality. Narrative synthesis of the evidence suggests a framework for viewing the cycle of functional and cognitive decline in the elderly with CDI, impacting the gut-brain and gut-muscle axes.

Indexed as

Clostridium InfectionsFrailtyAgedCognitionHumansQuality of LifeRisk FactorsAgingClostridioides difficile infectionCognitionFrailtyGut–brain axisMicrobiome

Identifiers

PMID37849008
PMCPMC10580652
OpenAlexW4387704877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.